Related Experiment Video
Updated: Feb 1, 2026
12:04
Assessment of the Cytotoxic and Immunomodulatory Effects of Substances in Human Precision-cut Lung Slices
Published on: May 9, 2018
14.7K
The adenosinergic immunomodulatory drugs
1New England Inflammation and Tissue Protection Institute, Northeastern University, 113 Mugar Health Science Building, 360 Huntington Avenue, Boston, MA 02115, United States. a.ohta@neu.edu
Current Opinion in Pharmacology
|June 23, 2009
Summary
Blocking adenosine A2A receptors (A2AR) can enhance anti-tumor immunity but may risk increased inflammation. Modulating these pathways offers potential therapeutic strategies for cancer and inflammatory diseases.
Area of Science:
- Immunology
- Pharmacology
- Oncology
Background:
- Extracellular adenosine increases in inflamed and cancerous tissues due to hypoxia.
- This adenosine plays a key role in regulating immune cell activity and tissue destruction.
- Adenosine-mediated immunosuppression is a significant factor in disease progression.
Purpose of the Study:
- To investigate the therapeutic potential of adenosine A2A receptor (A2AR) antagonists.
- To explore the role of A2AR signaling in anti-tumor and anti-pathogen immune responses.
- To evaluate the risks and benefits of modulating hypoxia-adenosinergic pathways.
Main Methods:
- Review of accumulated data on A2A adenosine receptor antagonists.
- Analysis of the effects of adenosine-A2AR signaling inhibition on immune responses.
- Consideration of patient risks associated with A2AR antagonists in inflammatory conditions.
Main Results:
- A2A adenosine receptor (A2AR) antagonists may diminish adenosine-mediated immunosuppression.
- Inhibition of adenosine-A2AR signaling can enhance anti-tumor and anti-pathogen immune responses.
- Patients with inflammatory disorders may face increased inflammatory damage from A2AR antagonists.
Conclusions:
- Inhibiting adenosine-A2AR signaling is a promising strategy for enhancing anti-cancer immunity.
- Careful consideration of patient risk is necessary due to potential increases in inflammatory damage.
- Enhancing hypoxia-adenosinergic pathways may offer protective benefits against inflammatory tissue destruction.
Related Concept Videos
01:26FDA Approved Drugs: Changes to Approved Drugs
268
Post-approval, manufacturers may modify an approved new or generic drug product. Such modifications can encompass alterations in the Active Pharmaceutical Ingredient (API), manufacturing process, formulation, batch size, manufacturing site, and container closure system (FDA Guidance for Industry, April 2004). Often, a drug product may undergo multiple changes.These modifications require careful evaluation to determine their potential impact on the drug product's identity, strength, quality,...
268
01:09Bioequivalence of Drugs: Drugs with Multiple Indications
158
The concept of therapeutic equivalence (TE) in drugs with multiple indications is complex. A generic drug may be therapeutically equivalent to a brand-name product for one specific indication, but this doesn't necessarily mean it's equivalent for all other indications. Evidence of TE in one patient group and bioequivalence shown in healthy volunteers can support—but not confirm—TE for other indications. However, definitive proof requires individual clinical studies for each...
158
01:25Pharmacokinetics: Drug–Drug Interactions
440
Drug interactions occur when the pharmacological effect of one drug is altered by another substance, either enhancing or diminishing its activity. The drug whose activity is altered is known as the object drug, and the substance causing the alteration is called the agent drug or the precipitant. The net effects of these interactions are mostly undesirable, leading to decreased effectiveness or increased adverse effects. In rare cases, interactions can be beneficial, such as the enhanced...
440
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
537
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
537
01:27Factors Influencing Drug Absorption: Drug Dissolution
1.2K
The pharmacokinetic journey of drugs from solid oral dosage forms into systemic circulation is multifaceted. It begins with disintegration, a prerequisite ensuring a solid dosage form's subdivision into minute particles. Dissolution occurs next as these granulated entities solubilize in gastrointestinal fluids. This solubilization is crucial for the succeeding stage, permeation, which describes the traversal of the drug across the intestinal membrane and its subsequent entry into the blood...
1.2K
01:18Factors Affecting Protein-Drug Binding: Drug-Related Factors
484
Drug binding to proteins is a complex phenomenon influenced by various drug-related factors, each playing a significant role in the interaction between drugs and proteins within the body.
One crucial factor in drug-protein binding is the drug's lipophilicity or its affinity for fat. More lipophilic drugs tend to have higher binding extents. For example, highly lipophilic drugs like cloxacillin exhibit substantial protein binding, with as much as 95% of the drug binding to proteins. In...
One crucial factor in drug-protein binding is the drug's lipophilicity or its affinity for fat. More lipophilic drugs tend to have higher binding extents. For example, highly lipophilic drugs like cloxacillin exhibit substantial protein binding, with as much as 95% of the drug binding to proteins. In...
484